FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2596946457> ?p ?o ?g. }

• W2596946457 endingPage "E521" @default.
• W2596946457 startingPage "E521" @default.
• W2596946457 abstract "No effective treatment that would reduce the incidence and severity of radiation-induced skin toxicity has been identified up to now. Epigallocatechin-3-gallate (EGCG), which helps in the healing process of erythema response evoked by UV radiation in human, may also alleviate symptoms of radiation dermatitis. We hypothesized that topical EGCG is effective in treating radiation dermatitis and conducted a single-arm phase 2 trial testing this hypothesis with patients undergoing adjuvant radiation therapy to the breast. Patients were treated with mastectomy followed by adjuvant radiation therapy (total dose, 50Gy) to the breast. Eligible patients were also required to have met the following criteria: age≥18 years; ECOG PS 0-1; no prior radiation to the thorax; adequate hematologic, hepatic function and renal values. The study was approved by the Institutional Review and Ethical Committees and registered at ClinicalTrials.gov. In addition, informed consent was obtained from all patients. Topical EGCG at 660μmol/L was applied daily, starting on the day only after the skin becomes grade I dermatitis and ending 2 weeks post-radiation therapy. Patients underwent weekly skin assessments throughout radiation therapy and at 2 weeks after RT-treatment. Outcome measures were assessed using an observer-assessment score that was defined by Radiation Therapy Oncology Group (RTOG) criteria and a self-assessment score that evaluated skin symptoms according to the adapted Skin Toxicity Assessment Tool (STAT). RT was delivered without treatment breaks to all 49 patients. Grade I dermatitis appeared in 17 patients during the second week, 24 during the third week, and 8 during the fourth week. In addition, the mean duration of EGCG treating time is 5 weeks. The personal maximum skin toxicity observed during the course of treatment was follows: Grade 1 toxicity, 71.4% (35 patients); Grade 2 toxicity, 28.6% (14 patients); more than Grade 2 toxicity, 0% (0 patients). Most importantly, the personal minimum skin toxicity received Grade 0 in 15 patients. There was a significant difference between onset and end of the study (P<0.05) in RTOG score. Patient-reported symptom scores were also significantly decreased at the end of the study in pain, burning, itching, and tenderness (P<0.05). It is possible for EGCG to significantly and continuously control the symptoms of pain (85.7% of patients), burning (89.8%), itching (87.8%), pulling (71.4%), and tenderness (79.6%). Topical EGCG treating the radiation-induced dermatitis is effective. Randomized controlled trials will establish to support the use of EGCG for the prevention and management of acute radiation skin reactions." @default.
• W2596946457 created "2017-03-23" @default.
• W2596946457 creator A5008057837 @default.
• W2596946457 creator A5015950934 @default.
• W2596946457 creator A5025970058 @default.
• W2596946457 creator A5039784240 @default.
• W2596946457 creator A5065003951 @default.
• W2596946457 creator A5085589805 @default.
• W2596946457 date "2015-11-01" @default.
• W2596946457 modified "2023-10-16" @default.
• W2596946457 title "Trial of Assessing the Effectiveness of Topical Epigallocatechin-3-Gallate as an Interventional Agent for Radiation-Induced Acute Skin Toxicity to the Breast in Women Undergoing Adjuvant Radiation Therapy" @default.
• W2596946457 doi "https://doi.org/10.1016/j.ijrobp.2015.07.1879" @default.
• W2596946457 hasPublicationYear "2015" @default.
• W2596946457 type Work @default.
• W2596946457 sameAs 2596946457 @default.
• W2596946457 citedByCount "0" @default.
• W2596946457 crossrefType "journal-article" @default.
• W2596946457 hasAuthorship W2596946457A5008057837 @default.
• W2596946457 hasAuthorship W2596946457A5015950934 @default.
• W2596946457 hasAuthorship W2596946457A5025970058 @default.
• W2596946457 hasAuthorship W2596946457A5039784240 @default.
• W2596946457 hasAuthorship W2596946457A5065003951 @default.
• W2596946457 hasAuthorship W2596946457A5085589805 @default.
• W2596946457 hasConcept C121608353 @default.
• W2596946457 hasConcept C126322002 @default.
• W2596946457 hasConcept C141071460 @default.
• W2596946457 hasConcept C143998085 @default.
• W2596946457 hasConcept C16005928 @default.
• W2596946457 hasConcept C168563851 @default.
• W2596946457 hasConcept C2777863537 @default.
• W2596946457 hasConcept C2779121184 @default.
• W2596946457 hasConcept C29730261 @default.
• W2596946457 hasConcept C509974204 @default.
• W2596946457 hasConcept C530470458 @default.
• W2596946457 hasConcept C535046627 @default.
• W2596946457 hasConcept C71924100 @default.
• W2596946457 hasConceptScore W2596946457C121608353 @default.
• W2596946457 hasConceptScore W2596946457C126322002 @default.
• W2596946457 hasConceptScore W2596946457C141071460 @default.
• W2596946457 hasConceptScore W2596946457C143998085 @default.
• W2596946457 hasConceptScore W2596946457C16005928 @default.
• W2596946457 hasConceptScore W2596946457C168563851 @default.
• W2596946457 hasConceptScore W2596946457C2777863537 @default.
• W2596946457 hasConceptScore W2596946457C2779121184 @default.
• W2596946457 hasConceptScore W2596946457C29730261 @default.
• W2596946457 hasConceptScore W2596946457C509974204 @default.
• W2596946457 hasConceptScore W2596946457C530470458 @default.
• W2596946457 hasConceptScore W2596946457C535046627 @default.
• W2596946457 hasConceptScore W2596946457C71924100 @default.
• W2596946457 hasIssue "3" @default.
• W2596946457 hasLocation W25969464571 @default.
• W2596946457 hasOpenAccess W2596946457 @default.
• W2596946457 hasPrimaryLocation W25969464571 @default.
• W2596946457 hasRelatedWork W1997906202 @default.
• W2596946457 hasRelatedWork W2066747782 @default.
• W2596946457 hasRelatedWork W2163676795 @default.
• W2596946457 hasRelatedWork W2413875651 @default.
• W2596946457 hasRelatedWork W2759031936 @default.
• W2596946457 hasRelatedWork W2769256842 @default.
• W2596946457 hasRelatedWork W2810905056 @default.
• W2596946457 hasRelatedWork W2948923376 @default.
• W2596946457 hasRelatedWork W2972384824 @default.
• W2596946457 hasRelatedWork W3162555034 @default.
• W2596946457 hasVolume "93" @default.
• W2596946457 isParatext "false" @default.
• W2596946457 isRetracted "false" @default.
• W2596946457 magId "2596946457" @default.
• W2596946457 workType "article" @default.